uniQure Stock Falls as Investors Await Key Huntington's Disease Data

Shares of uniQure NV (NASDAQ: QURE) slid nearly 7.0% in morning trading to $39.80 as investors reduced exposure ahead of a highly anticipated clinical data release. The decline is primarily driven by caution surrounding the upcoming four-year topline results for AMT-130, the company's lead gene therapy candidate for Huntington’s disease.

Pivotal Data Release Looms

The upcoming data from the Phase I/II trial of AMT-130 represents a significant binary event for uniQure. Management has guided that the results will be released by September 30, 2026. Positive results could validate the long-term efficacy and durability of the treatment, while disappointing data could present a major setback.

This uncertainty is prompting shareholders to trim positions to mitigate risk ahead of the announcement. The stock has been under pressure for weeks, extending a pullback that began in late August and has pushed shares down roughly 44% from a 52-week high of $71.50.

Ad

Market Headwinds and Technical Pressure

Compounding the anxiety around the clinical trial is a challenging macroeconomic environment. Major U.S. indices, including the S&P 500 and Nasdaq, were trading lower amid rising Treasury yields, as investors anticipate further interest rate hikes from the Federal Reserve.

This risk-off sentiment disproportionately affects pre-revenue biotechnology firms like uniQure, whose valuations are highly sensitive to changes in discount rates and investor risk appetite. According to Investing.com, which cited analysts at StockInvest, technical indicators also signaled weakness, with an increase in trading volume on falling prices and identified resistance levels at $43.72 and $46.31.